REPURPOSING OF AN APPROVED DRUG SPECIFIC FOR VARIOUS NEUROLOGICAL CONDITIONS
Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
ASX ANNOUNCEMENTS
PRESENTATION
5 July 2019 – Invex Therapeutics – Repurposing An Approved Drug
SUBSCRIBE TO UPDATES
MEDIA
- 13/07/2019 - Professor Sinclair addresses IIH UK Patient Conference
- 11/07/2019 - Invex featured in Yahoo Finance and Motley Fool
- 09/07/2019 - Prestigious JAMA Neurology medical journal publishes Prof Sinclair’s study into IIH
- 09/07/2019 - Announcement by University of Birmingham
- 09/07/2019 - Invex Therapeutics debuts on ASX trading up over 100%
PARTNERS
CONTACT INFORMATION
Address
Level 1, 38 Rowland St
Subiaco Perth WA 6008
Phone
+61 (08) 6382 0137
ACN 632145334
Disclaimer. Copyright © Invex Therapeutics. All rights reserved. Site developed by NFIC Services.